HCC

Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)

Retrieved on: 
Friday, November 3, 2023
Regulatory T cell, IRF1, Neoplasm, CCR8, FDA, Survival, PD-L1, HCC, NSCLC, Chemokine, Food, Renal cell carcinoma, Biomarker, ESCC, Head, PD-1, CHRS, Teff, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Inflammation, Cell, NPC, RCC, Interleukin, CD8, SITC, Poster, Nasopharyngeal carcinoma, Apoptosis, NK, Immunity, Immune system, Gene, Tumor microenvironment, Lung cancer, SHP2, Cancer, Hepatocellular carcinoma, GBP5, TME, Drug resistance, Patient, IL-27, Gene expression, Vaccine, Pharmaceutical industry, Office supplies, SHP1, HNSCC

REDWOOD CITY, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced data from three immuno-oncology pipeline programs at the 38th Annual Meeting of SITC taking place November 1 - 5, 2023 at the San Diego Convention Center in San Diego, CA. Preclinical data presented support differentiated mechanisms of its next-generation immunotherapies potentially enabling the antitumor immune activation in more cancer patients and enhanced treatment outcomes.

Key Points: 
  • Preclinical data presented support differentiated mechanisms of its next-generation immunotherapies potentially enabling the antitumor immune activation in more cancer patients and enhanced treatment outcomes.
  • CCR8 is a chemokine receptor predominantly expressed by tumor infiltrating Tregs that suppress the body’s natural anti-cancer immune response.
  • Targeting CCR8 is a promising potential therapeutic strategy designed to deplete Tregs, reshape the tumor microenvironment and enhance anti-tumor immune response.
  • Data presented compare mechanistic data for LOQTORZI™ to commercially available anti-PD-1 monoclonal antibodies and demonstrate higher expression of key immune system biomarkers with LOQTORZI™.

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

Retrieved on: 
Thursday, November 2, 2023
Neoplasm, HCC, NSCLC, PD, Renal cell carcinoma, Therapy, Cancer, ESCC, SCCHN, Head, MSI-H, RCC, Pharmacokinetics, Mesothelioma, Lung cancer, Melanoma, Safety, Hepatocellular carcinoma, TME, Patient, Carcinoma, Neck, Pharmaceutical industry

AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors.

Key Points: 
  • AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors.
  • The Phase 1 study is a multi-center open-label, dose-escalation, dose-expansion, and a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary efficacy of MT-8421.
  • Approximately 24-30 patients are anticipated to enroll in Part A dose escalation with a starting dose of 32 mcg/kg.
  • “We look forward to this approach providing patient benefit in this first-in-human study.”

Howard County Executive Calvin Ball Announces $10 Million Investment in Howard Community College's Workforce Development and Skilled Trades Center

Retrieved on: 
Wednesday, November 1, 2023
Howard Community College, Learning, California State Association of Counties, Workforce, County, HCC, Niche, Student, Geography, Management, Nursing, MD

Columbia, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Howard County Executive Calvin Ball announced a $10 million funding commitment to Howard Community College (HCC) to help the institution build a workforce development and skilled trades center.

Key Points: 
  • Columbia, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Howard County Executive Calvin Ball announced a $10 million funding commitment to Howard Community College (HCC) to help the institution build a workforce development and skilled trades center.
  • "This center will be a beacon of innovation and increase our economic vitality statewide," said Dr. Ball in his remarks.
  • The trades center will be the first of its kind in the county and will directly address a growing statewide shortage of skilled workers in trades and technical fields.
  • To learn more about the Workforce Development & Skilled Trades Center capital campaign, please visit our website .

HCC Launches $11 Million Campaign for Workforce Development & Skills Trades Center

Retrieved on: 
Tuesday, October 31, 2023
HCC, Innovation, Howard Community College, Local, Niche, School, Language Studies International, Nursing, Management, MD, Workforce

Columbia, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Howard Community College (HCC) President Daria J. Willis announced the launch of an $11 million capital campaign in support of a new campus-based workforce development and skilled trades center.

Key Points: 
  • Columbia, MD, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Howard Community College (HCC) President Daria J. Willis announced the launch of an $11 million capital campaign in support of a new campus-based workforce development and skilled trades center.
  • "One of my priorities as president is to establish the trades center as a direct anti-poverty and racial equity resource for Howard County," said Dr. Willis.
  • "Maryland is an emerging national leader in workforce innovation," said Minah Woo, HCC Vice President of Workforce, Innovation and Strategic Partnerships.
  • To learn more about the Workforce Development & Skilled Trades Center capital campaign, please visit our website .

Edifecs to Speak on the Power of Artificial Intelligence at 2023 WEDI National Conference

Retrieved on: 
Monday, November 6, 2023
Technology, Health Technology, Software, Networks, Practice Management, Internet, General Health, Health, Data Management, Artificial Intelligence, Washington College of Law, Electronic data interchange, HCC, National Conference, CDI, Workgroup for Electronic Data Interchange, American University of Antigua, News, Conference, Thin Air (Morgan novel), Generative, Washington College, Workgroup, Artificial intelligence, Artificial intelligence in healthcare, Health equity, WEDI, American University, Medical record, EHR, AI, HEDIS, Patient, DRG, Risk-adjusted return on capital, Software as a service, Medical device, Ridesharing

Edifecs, a leader in healthcare AI, has long offered cloud-powered Software-as-a-Service (SaaS) to deliver proven AI-driven solutions for payers, providers, and the healthcare ecosystem at large.

Key Points: 
  • Edifecs, a leader in healthcare AI, has long offered cloud-powered Software-as-a-Service (SaaS) to deliver proven AI-driven solutions for payers, providers, and the healthcare ecosystem at large.
  • The Edifecs AI-driven technology runs across frameworks, including risk adjustment, value-based payment, and prior authorization.
  • Edifecs’ 2023 WEDI National Conference Engagement:
    WHAT: In the era of value-based care, achieving excellence in patient care is paramount.
  • WHERE: American University's Washington College of Law, NT01, Ceremonial Classroom
    For updates on the latest news and announcements at the conference, please follow Edifecs on LinkedIn .

Warrior Reports Third Quarter 2023 Results

Retrieved on: 
Wednesday, November 1, 2023
Natural Resources, Coal, Other Manufacturing, Energy, Steel, Other Natural Resources, Mining, Minerals, Manufacturing, Adjustment, 2021–2023 Warrior Met Coal strike, Pacific Ocean, HCC, Second Amendment to the United States Constitution, NYSE, Policy, Note, Senior, Transport, PLB, Depreciation, Capital expenditure, Retirement, Capital allocation line, Credit, Mine, Sustainability Accounting Standards Board, Action Replay, Offers, Capital, Iron ore, Video game, Security (finance), Arms industry, Bank, Warrior

Warrior Met Coal, Inc. (NYSE: HCC) (“Warrior” or the “Company”) today announced results for the third quarter of 2023.

Key Points: 
  • Warrior Met Coal, Inc. (NYSE: HCC) (“Warrior” or the “Company”) today announced results for the third quarter of 2023.
  • Warrior reported net income for the third quarter of 2023 of $85.4 million, or $1.64 per diluted share, a decrease from net income of $98.4 million, or $1.90 per diluted share, in the third quarter of 2022.
  • The Company reported Adjusted EBITDA of $145.8 million in the third quarter of 2023 compared to Adjusted EBITDA of $171.6 million in the third quarter of 2022.
  • Cost of sales for the third quarter of 2023 were $260.4 million compared to $203.4 million for the third quarter of 2022.

CatalYm Presents Data at SITC 2023 Annual Meeting Further Unraveling GDF-15-mediated Inhibition of T Cell Adhesion and a New Combination Approach for Visugromab with Bispecific T-Cell Engagers

Retrieved on: 
Tuesday, October 31, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, HCC, Society for Immunotherapy of Cancer, NSCLC, Nivolumab, Bladder cancer, Cell adhesion, Phosphorylation, SITC, Immunotherapy, Annual general meeting, Tumor microenvironment, Lung cancer, Safety, Society, Cancer, Hepatocellular carcinoma, Patient, Pharmaceutical industry, Vaccine

Visugromab is currently evaluated in a broad Phase 2 program in combination with anti-PD-1 treatment in multiple solid tumor indications.

Key Points: 
  • Visugromab is currently evaluated in a broad Phase 2 program in combination with anti-PD-1 treatment in multiple solid tumor indications.
  • “The new data for the combination of visugromab with bispecific T-cell engagers provide strong scientific support for a synergistic effect in this novel therapeutic setting.
  • When investigating the involvement of additional cell adhesion pathway components downstream of GDF-15, SHP-1 was identified as a central mediator of GDF-15-related inhibition of T cell adhesion.
  • In addition, CatalYm recently announced an exploratory Phase 2 study , GDFather-NEO ( NCT06059547 ), evaluating visugromab in combination with neoadjuvant immunotherapy in first-line muscle-invasive bladder cancer.

Swinerton Announces New Leadership Team to Drive Growth in Seattle

Retrieved on: 
Tuesday, October 31, 2023
Emerald, Knowledge, Chalmers, Roger W. Jones Award for Executive Leadership, CBP Office of Field Operations, HCC, Heart, Mentorship, Homelessness, Health care, Brooks, Pacific Northwest, United States Navy Special Projects Office, Bellevue Towers, Construction, Eastgate, American Heart Association, Tenant, Puyallup people, Risk management, Medicine, Hard Hats, Stearns, Pharmacy, RFP, Consultant, Health, Mass, Project executive, Safety, Tribe, Education Committee, Communication, League of Ireland Premier Division Manager of the Year, Management, Swinerton, Bellevue Square, Native

SEATTLE, Oct. 31, 2023 /PRNewswire-PRWeb/ -- Swinerton, a leading construction company with a national presence, is proud to unveil its newly appointed leadership team within the Seattle Division. This dynamic team, comprised of seasoned industry professionals, is poised to reinforce Swinerton's position as a premier contractor in the Seattle area. These individuals bring extensive experience and expertise to their respective roles, further enhancing the firm's commitment to delivering excellence in construction services.

Key Points: 
  • SEATTLE, Oct. 31, 2023 /PRNewswire-PRWeb/ -- Swinerton, a leading construction company with a national presence, is proud to unveil its newly appointed leadership team within the Seattle Division.
  • "The new leadership team brings a wealth of experience and a shared commitment to excellence, positioning Swinerton for continued success in the Seattle area," states Nick Vovakas, Vice President and Division Manager of Swinerton's Seattle Division.
  • As announced in June, Nick Vovakes will lead the new leadership team as Vice President and Division Manager.
  • "The new leadership team brings a wealth of experience and a shared commitment to excellence, positioning Swinerton for continued success in the Seattle area," states Vovakes.

Health care culture expert to headline RISE's 22nd Risk Adjustment Forum

Retrieved on: 
Tuesday, October 31, 2023
HCC, Affordable Care Act, Centers for Medicare & Medicaid Services, Education, Medicare, Medicare Advantage, Risk-adjusted return on capital, Risk, Medicaid, Culture, Communication, Mobile phone, DALLAS, Bartholomew the Apostle

 DALLAS, Oct. 31, 2023 /PRNewswire/ -- Kathleen Bartholomew, R.N., MN, named one of the top 20 people changing health care in America, will be the keynote speaker at the 22nd Risk Adjustment Forum, the premier event for risk adjustment and quality specialists in the health care industry, which will take place November 27-29, 2023, at the Fairmont Dallas.

Key Points: 
  • Kathleen Bartholomew, R.N., MN, an expert on the power of culture, will kick off the first day of the main conference with a presentation on how to lead through change.
  • DALLAS, Oct. 31, 2023 /PRNewswire/ -- Kathleen Bartholomew, R.N., MN, named one of the top 20 people changing health care in America, will be the keynote speaker at the 22nd Risk Adjustment Forum , the premier event for risk adjustment and quality specialists in the health care industry, which will take place November 27-29, 2023, at the Fairmont Dallas.
  • The three-day Risk Adjustment Forum, which includes four pre-conference workshops, is designed for executives in Medicare Advantage, Medicaid managed care, and Affordable Care Act plans who seek updated best practices and strategies for coding accuracy and education success.
  • The Risk Adjustment Forum will take place November 27-29, 2023, at the Fairmont Dallas.

Hepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer Model

Retrieved on: 
Wednesday, October 25, 2023
Liver, Neoplasm, HCC, Mouse, Health, Conditional sentence, Virus, Sofosbuvir, Artificial intelligence, Scripps Research, Growth, Liver cancer, HCV, Fatty liver disease, DRS, Velpatasvir, HEPA, Cancer, Pharmaceutical industry, Medical imaging, Dietary supplement

The study was published in the peer-reviewed, open access scientific journal, Viruses, and was conducted by Drs.

Key Points: 
  • The study was published in the peer-reviewed, open access scientific journal, Viruses, and was conducted by Drs.
  • Winston Stauffer, Philippe Gallay, and colleagues at The Scripps Research Institute (La Jolla, California).
  • Sofosbuvir, velpatasvir and rencofilstat treatments initiated at week 16 all eliminated HCV infection.
  • Not only could rencofilstat have an enormous impact on human health, but the investment growth opportunities associated with treating these high-need, global-scale diseases are equally large.”
    Hepion recently announced a new mechanism by which rencofilstat exerts anti-cancer activity in liver cancer and the drug’s anti-cancer activity in numerous cell lines representing 86% of cancer types.